Pegasus Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Pegasus Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,000	Closed	-$22.9K	–	72
2023 Q2	$22.9K	Hold	10,000	–	–	0.01%	72
2023 Q1	$24.3K	Hold	10,000	–	–	0.01%	70
2022 Q4	$19.1K	Hold	10,000	–	–	0.01%	72
2022 Q3	$24K	Hold	10,000	–	–	0.01%	72
2022 Q2	$19K	Hold	10,000	–	–	0.01%	72
2022 Q1	$21K	Hold	10,000	–	–	0.01%	77
2021 Q4	$39K	Hold	10,000	–	–	0.02%	76
2021 Q3	$48K	Hold	10,000	–	–	0.02%	76
2021 Q2	$46K	Hold	10,000	–	–	0.02%	74
2021 Q1	$59K	Hold	10,000	–	–	0.03%	73
2020 Q4	$34K	Hold	10,000	–	–	0.02%	71
2020 Q3	$14K	Hold	10,000	–	–	0.01%	71
2020 Q2	$20K	Hold	10,000	–	–	0.01%	70
2020 Q1	$20K	Hold	10,000	–	–	0.02%	66
2019 Q4	$42K	Hold	10,000	–	–	0.03%	71
2019 Q3	$30K	Hold	10,000	–	–	0.02%	69
2019 Q2	$63K	Hold	10,000	–	–	0.05%	68
2019 Q1	$56K	Hold	10,000	–	–	0.05%	66
2018 Q4	$66K	Buy	+10,000	New	+$81K	0.06%	67

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Pegasus Asset Management's LXRX Position: Q3 2023 in Review

Pegasus Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2023, closing a stake of 10,000 shares — an estimated $22.9K sold.

Pegasus Asset Management first reported a position in LXRX in Q4 2018 and held it in 19 quarters. The position peaked at $66K in Q4 2018. 112 funds tracked by Wall St. Rank hold LXRX as of Q3 2023.

Pegasus Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Pegasus Asset Management sold 10,000 Lexicon Pharmaceuticals shares in Q3 2023, an estimated $22.9K.
Pegasus Asset Management first reported a position in Lexicon Pharmaceuticals in Q4 2018 and held it in 19 quarters.
Pegasus Asset Management's Lexicon Pharmaceuticals position peaked at $66K in Q4 2018.
112 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2023.

Based on Pegasus Asset Management's 13F filing for Q3 2023, filed 2 Nov 2023.